Business

Bristol-Myers to Stop New Antiviral Drug Research

A sign stands in front of the Bristol-Myers Squib Company's headquarters in Lawrence Township in 2005. (AP Photo/Mel Evans)
A sign stands in front of the Bristol-Myers Squib Company’s headquarters in Lawrence Township in 2005. (AP Photo/Mel Evans)

 

(Reuters) – Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs.

The company said it will also discontinue its Hepatitis B and HIV early programs.

Bristol-Myers said already marketed products and its ongoing clinical programs in virology would not be hit by the decision.

The company is seeking U.S. approval for its experimental hepatitis C drug, daclatasvir.

READ MORE

Tags
Show More

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker